tert-butyl (4S)-4-(2-cyclopropylethyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate | 1222186-29-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: tert-butyl (4S)-4-(2-cyclopropylethyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
• 英文别名: (S)-tert-butyl 4-(2-cyclopropylethyl)-2,2-dimethyloxazolidine-3-carboxylate
• CAS: 1222186-29-9
• 化学式: C₁₅H₂₇NO₃
• 分子量: 269.384
• InChiKey: WFFHPEURVCCART-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (4S)-4-(2-cyclopropylethyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 在 ruthenium trichloride 、 sodium periodate 、 对甲苯磺酸 作用下， 以 甲醇 、 氯仿 、 水 、 乙腈 为溶剂， 反应 10.0h， 生成 (S)-2-((tert-butoxycarbonyl)amino)-4-cyclopropylbutanoic acid
  参考文献：
  名称：

  [EN] ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS
  [FR] COMPOSÉS DEPSIPEPTIDIQUES ANTHELMINTHIQUES

  摘要：

  本发明提供了公式（I）的环脱氨肽化合物和包含这些化合物的组合物，这些化合物对危害动物（包括人类）的寄生虫具有有效性。这些化合物和组合物可用于对抗哺乳动物和鸟类体内或体外的寄生虫。该发明还提供了一种改进的方法，用于根除、控制和预防动物（包括鸟类和哺乳动物）的寄生虫感染。

  公开号：

  WO2017116702A1
• 作为产物：
  描述：

  (S)-tert-butyl 4-(2-cyclopropylvinyl)-2,2-dimethyloxazolidine-3-carboxylate 在 sodium acetate 、 对甲苯磺酰肼 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 4.0h， 以95%的产率得到tert-butyl (4S)-4-(2-cyclopropylethyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
  参考文献：
  名称：

  Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species

  摘要：

  Hepatitis is a disease characterized by inflammation of the liver, usually producing swelling and, in many cases, permanent damage to liver tissues. Viral hepatitis C (HCV), a small (+)-RNA virus, infects chronically 3% of the world's population. Boceprevir, SCH 503034, (1) our first generation HCV inhibitor, has already established proof-of-concept and is currently in late stage (phase III) clinical trials. In view of the positive data from our first generation compound, further work aimed at optimizing its overall profile was undertaken. Herein, we report that extension of our earlier inhibitor to the P-4 pocket by introducing a new sulfonamide moiety and optimization of the P1/P-1' capping led to the discovery of a novel series of inhibitors of the HCV NS3 serine protease. Optimization of the P-1 residue significantly improved potency and selectivity. The combination of optimal moieties led to the discovery of compound 47 which, in addition to being a potent inhibitor of HCV subgenomic RNA replication, was also found to have good PK profile in rat, dog and monkey. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.01.044

文献信息

• Anthelmintic depsipeptide compounds
  申请人：BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.

  公开号：US10344056B2

  公开（公告）日：2019-07-09

  The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals, including humans. The compounds and compositions may be used for combating parasites in or on animals including mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in animals, including birds and mammals.

  本发明提供了式(I)的环状去肽化合物和含有该化合物的组合物，它们能有效地防治危害动物（包括人类）的寄生虫。这些化合物和组合物可用于防治包括哺乳动物和鸟类在内的动物体内或身上的寄生虫。本发明还提供了一种根除、控制和预防动物（包括鸟类和哺乳动物）体内寄生虫侵扰的改进方法。
• ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS
  申请人：MERIAL INC.

  公开号：US20170233438A1

  公开（公告）日：2017-08-17

  The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals, including humans. The compounds and compositions may be used for combating parasites in or on animals including mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in animals, including birds and mammals.